Latanoprost: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PHARMAC (New Zealand) and SMC (Scotland) recommended or restricted latanoprost, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 21.2 years separate the first record, 12 Jul 2004 at SMC (Scotland), from the most recent, 24 Sep 2025 at HAS (France).
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 4 of 17 records date from 2023 or later.
3 distinct indication wordings are recorded for latanoprost by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess latanoprost, on 12 Jul 2004; AWMSG (Wales) did not open a file until 11 Oct 2011 — a wide spread of 7.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 12 years in total.
3 of the 4 agencies here assessed latanoprost more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed latanoprost.
The full ledger for latanoprost reads 10 recommended, 3 other, 2 restricted and 1 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 24 Sep 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 9 Oct 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| SMC (Scotland) | 8 Jul 2013 | For the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension. | accepted (restricted) | source |
| AWMSG (Wales) | 25 Jan 2013 | Reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension | outside AWMSG criteria | source |
| PHARMAC (New Zealand) | 5 Aug 2010 | Glaucoma | PTAC advice: Cost Neutral · decision reached | source |
12 further decisions for latanoprost, across 3 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- bimatoprost — same ATC class S01E — Ophthalmologicals
- travoprost — same ATC class S01E — Ophthalmologicals
- dorzolamide / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / timolol — same ATC class S01E — Ophthalmologicals
- bimatoprost / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / netarsudil — same ATC class S01E — Ophthalmologicals
Coverage: 17 decisions for latanoprost from 4 agencies, 2004 to 2025. Data to 7 Sep 2026. ATC class S01E — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.